New fair value I’ll keep this brief. Regardless of how long you’ve held this stock, the question around what is “fair value” is now reset after Friday’s news, and depends on demand more than speculation. The tech works. We longs paid a huge risk premium, seen as a stock valuation in the pennies, prior to now. This was well below what elements of our technology, were trading for when big pharma swooped in and bought those elements.
Now it’s our turn. Big Pharma waited for the results to “prove out” and based on a small sample size they waited too long if they thought they’d get a bargain.
The value re-calculation seen on Friday is nothing compared to what Phillip and the board now oversee. Part A is finally behind us (longs). Thank you for getting an excellent researcher in Chicago! Part B is getting full value for our commitment, which may take another year of results, but could make Friday’s gains seem quaint. I’ve updated my $2+ prediction from June 2020. That value should be achieved by the time patients 2-5 are stabilized and insulin free. After that there multiples of $2 yet to tested.
DF